**Appendix Table C75. Participant characteristics: Comparator, glial tumors**

| **Study (Investi-gator, country, year)** | **Record Num-ber** | **Group (N)** | **Age (mean)** | **Age (median)** | **Age (Range)** | **Age (SD)** | **Race (%)** | **Gender M, F (%)** | **Disease Stage/category** | **Disease Histology/Site (%)** | **Comment** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Ayan, Turkey, 1995 | 74690 | Anaplastic ependymoma 4 |   | 12.5 years | 5-15 years |   |   | 3, 1 (75, 25%) | Anaplastic 4 (100%) | frontal lobe 1 (25), temporoparietal-occipital lobe 1 (25%), Multiple parenchymal meningial lesions 1 (25%), Temporoparietal lobe 1 (25%). CSF cytology positive in one patient (25%) |   |
| Berger, France, 1998 | 75380 | Choroid plexus carcinoma (22) |   | 31 mo | 4-111 mo |   |   | 9, 11 (35, 55) | 3 patients had metastases at diagnosis (2 spinal/bifocal, 1 bifocal) 4 patients had no metastases and 13 patients had unknown metastases | 12 supratentorial (60), 8 infratentorial (40) |   |
| Bertolone, United States, 2003 | 10380 | 18 |   | 4 | <1 year - 16 years |   | NR | 11, 8 (58, 42) |   | 11 Anaplastic Astrocytoma (61), 3 Ependymoma (17), 2 Glioblastoma multiforme (11), 1 Anaplastic mixed glioma (6), 1 anaplastic ganglioglioma (6) |   |
| Conter, France, 2009 | 73540 | Ependymoma 24 |   | 8.6 years | 5-17 years |   |   | 16, 8 (67, 33) | Grade 2 13 (57), Grade 3 10 (43) | Supratentorial 4 (17), Infratentorial 20 (83) |   |
| Doireau, France, 1998 | 55990 | 8 | 4.6 | 3.8 | 3 mo - 4.5 |   |   | nr | Six patients had low-grade tumors while two had grade III tumors. All tumors were progressive and three had metastases before chemotherapy. | 5 astrocytoma (63), 3 oligoastrocytoma (37) | Ages at diagnosis |
| Finlay, United States | 1300 | 56 | nr | 11.1 | .1-19.3 | nr | nr | 29,27 (52,48%) | NR | Glioblastoma Multiform 27 (48%) Aplastic Astrocytoma 29 (52%) |   |
| Grill, France, 2001 | 74360 | Ependymoma 73 |   | 27 months | 5-62 months |   |   | 40, 33 (55, 45) | 73 Ependymoma 100% | 56 (82%) of patients had a high grade tumor, 12 (18%) had a low-grade tumor | 5 patients were not assigned a histological grade |
| Grundy, United Kingdom, 2007 | 73750 | Metastatic ependymoma 9, non-metastatic ependymoma 80 |   | 1.93, 1.36 | (.05-3.16), (.24-2.25) |   |   | 54 (67.5 % male), 4 (44 % male) | Non-metastatic 80 (90), Metastatic 9 (10) | Infratentorial 69 (86), Supratentorial 11 (14) Infratentorial 7 (78), Supratentorial 2 (22) WHO II 54 (68), WHO III 26 (32) WHO II 5 (56), WHOIII (44) |   |
| Grundy, United States, 2010 | 51800 | 41 |   | High Grade Glioma 1.8 years, Brain Stem Glioma 2.52 years | High Grade Glioma .33-3.09 years, Brain Stem Glioma .68-3.01 years |   |   | 18, 8 (69) | HGG: Anaplastic Astrocytoma 7, Astroblastoma 1, Anaplastic oliodendroglioma 2, Glioblastoma 5, unknown 3 Diffuse pontine glioma: diffuse astrocytoma 1, glioblastoma 1, unclassified 1, inoperable 4 | High Grade Glioma 19 (73), Brain Stem Tumor 7 (27) HGG metastatic in posterior fossa 2 (11), metastatic in supratentorial 17 (89) Brain Stem Glioma metastatic in Brainstem 7 (100), 15 cpc |   |
| Horn, United States, 1999 | 74470 | Ependymoma 83 |   | 51.5 mo | 8mo - 20 years |   |   | 50, 33 (60, 40) | M0 61 (85), M1-M3 11 (15) | WHO II grade 2 51 (61), WHO II grade 3 31 (37) Infratentorial 64 (77), Supratentorial 19 (23) | Age ≤ 3 29 \*=(35), Age >3 54 (65) |
| Hurwitz, United States, 2001 | 53330 | 45 |   | 7.7 | 4mos-19yr |   | NR | 56, 44% | Recurrent or progressive disease | Astrocytoma 4 (9), Malignant Glioma 13 (29), Brain Stem Glioma 15(33), Ependymoma 13 (29) | Age and Gender reported for entire 75 enrolled pts, not available by histology |
| Jaing, Taiwan, 2004 | 74030 | Ependymoma 43 |   | 6.6 years | 8 months to 18 years |   |   | 25, 18 (58, 42) | Grade II 20 (47), Grade III [anaplastic] (53) | Supratentorial 15 (35), Infratentorial (65) |   |
| Kobrinsky, United States, 1999 | 53560 | 42 | NR | NR | NR | NR | White 63, Black 12, Hispanic 19, Asian 3, Other/Mixed 3 | Male 54, Female 45 | NR | High grade astrocytoma 20 (48), Brain stem glioma 22 (52) | Race and sex statistics reported for the sum total 99 patients |
| Korones, United States, 2006 | 52670 | 9 | 12.2 | 9 | 5-21 |   | NR | 7,2 (77,23%) |   | 5 Glioblastoma, 2 anaplastic astrocytoma 2 brainstem glioma |   |
| Kuhl, Germany, 1998 | 17700 | 21 |   |   | 3-16 |   |   |   | 19 anaplastic (90), 14 infratentorial (67). 29% of patients had microscopic tumor cells in CSF | 21 ependymoma (100%) |   |
| Macdonald, United States, 2005 | 55000 | 76 |   | 11.95yrs | 3-20yrs |   | 69.7% white, 14.5% Hispanics, 10.5% Blacks, and 5.3% other | 36, 40 (47. 53%) | All patients had histologic verification of high-grade astrocytoma | GMB/GV 40 (53), AA 30 (39), Other 6 (8)supratentorial tumor 86.8%, five patients had metastatic disease | 4 patients not evaluable because imaging reports demonstrating residual disease were not available before chemotherapy |
| Merchant, United States, 2002 | 74280 | Ependymoma 64 |   | 3 years | 1.1 - 22.9 years |   |   | 32, 32 (50, 50%) | 45 differentiated ependymoma (70), 19 anaplastic ependymoma (30) |   |   |
| Robertson, United States, 1998 | 74630 | 32 |   | 7 | 2-17.3 |   | Caucasian 22 (69), African American 3 (9), Hispanic 4 (13), Other 3 (9) | 17, 15 (53, 47) | Anaplastic 12 (38) | posterior fossa 21 (66), supratentorial 11 (34) |   |
| Sio, Italy, 2006 | 6950 | 14 | 9.6 | 8.4 | 4.2-19.6 |   | nr | 9, 5 (64, 36) |   | Ependymoma 2 (14), Anaplastic Astrocytoma 3 (21), Brain Stem Glioma 8 (57), Glioblastoma Multiforme 1 (7) |   |
| Wrede, Germany, 2009 | 75590 | 34 CPC |   | 2.3 years | .3-17.1 years |   |   | 17, 17 (50, 50%) | Metastatic 7 (21%) | Lateral Ventricle 30 (88%), Fourth ventricle 4 (12%) |   |